Gennex Laboratories Ltd

BSE: GENNEX531739ISIN INE509C01026

Healthcare
Pharmaceuticals

BSE listing

Share price

₹10.27-0.16 (-1.53%)

as of 18 Sep 2026

52W high: ₹17.25
52W low: ₹7.05
Off 52W high: -40.46%
1M return: -12.74%
3M return: -2.10%
6M return: +9.26%
1Y return: -20.57%
20D avg volume: 7,26,350
50 DMA: ₹10.41
200 DMA: ₹11.11

Key ratios Consolidated

Market cap: ₹233.59 Cr
Current price: ₹10.27
52W high / low: ₹17.25 / ₹7.05
Face value: ₹1.00
P/E: 12.09
P/B: —
EPS (TTM): ₹0.85
Book value / share: —
ROE: —
ROCE: 9.90%
Operating margin: —
Net margin: —
Debt / equity: 0.15
Net debt: ₹35.89 Cr
Interest cover: 6.53
Dividend yield: —
Dividend / share (TTM): —
Payout: —
Cash conversion cycle: 163.0 days

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q4 FY24
Income statement
	39.84	60.95	40.37	37.24	34.18	40.33	—
	2.01	1.32	2.59	2.06	2.28	3.83	—
	36.93	57.61	36.01	33.24	30.59	40.20	—
	29.67	55.29	29.96	30.56	23.82	33.06	—
	0.00	0.00	0.00	0.00	0.00	0.00	—
	1.98	1.17	2.34	1.84	2.69	2.08	—
	0.90	1.08	1.11	1.03	0.98	1.20	—
	0.57	1.16	0.52	0.47	0.50	0.54	—
	3.85	1.58	3.75	4.50	4.22	4.09	—
	4.92	4.67	6.94	6.06	5.87	3.95	—
	0.00	0.00	-0.30	0.00	0.00	0.00	—
	4.92	4.67	6.64	6.06	5.87	3.95	—
	0.25	0.21	0.65	0.55	0.85	0.88	—
	4.67	4.46	5.99	5.51	5.02	3.07	—
	0.19	0.16	0.22	0.21	0.22	0.13	—
Key metrics
	6.39	6.91	8.27	7.56	7.35	5.69	—
	16.00%	11.30%	20.50%	20.30%	21.50%	14.10%	—
	11.70%	7.30%	14.80%	14.80%	14.70%	7.60%	—
	—	2.10%	—	2.50%	—	2.40%	—
	16.60%	51.10%	—	—	—	—	—
	-7.00%	45.30%	—	—	—	—	—

Metric	TTM	FY26	FY25	FY24
Income statement
	178.40	172.74	137.90	—
	7.98	8.25	10.43	—
	163.79	157.75	126.93	—
	145.48	139.62	100.59	—
	0.00	0.00	0.00	—
	7.33	8.04	8.35	—
	4.12	4.20	3.61	—
	2.72	2.65	1.99	—
	13.68	14.34	15.90	—
	22.59	23.24	21.40	—
	-0.30	0.00	0.00	—
	22.29	23.24	21.40	—
	1.66	2.26	3.27	—
	20.63	20.98	18.12	—
	0.78	0.76	0.79	—
Key metrics
	29.13	30.09	27.00	—
	16.33%	17.40%	19.60%	—
	11.56%	12.10%	13.10%	—
	—	9.90%	11.80%	—
	—	25.30%	—	—
	—	15.80%	—	—
	—	-75.59	-19.75	—
	—	-3.03	-0.60	—
	—	0.15	0.05	—
	—	35.89	9.67	—
	—	163.0	97.8	—
Balance sheet
	—	348.68	256.04	—
	—	264.66	181.13	—
	—	0.06	0.55	—
	—	43.56	14.16	—
	—	53.89	35.94	—
	—	5.55	4.69	—
	—	57.80	56.61	—
	—	20.30	13.16	—
	—	72.40	44.55	—
	—	35.95	10.22	—
	—	35.95	10.22	—
	—	0.00	0.00	—
	—	232.84	194.59	—
Cash flow
	—	-63.65	-10.80	—
	—	-4.80	0.82	—
	—	65.30	4.57	—
	—	11.94	8.95	—

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q4 FY24
Income statement
	34.68	36.71	28.18	29.33	25.64	23.28	—
	2.00	1.30	2.54	2.04	2.26	2.87	—
	32.47	34.81	25.46	26.13	23.05	23.97	—
	26.01	33.84	18.15	26.57	18.27	21.45	—
	0.00	0.00	0.00	0.00	0.00	0.00	—
	1.66	0.83	2.09	1.88	1.88	1.89	—
	0.51	0.63	0.69	0.55	0.59	0.53	—
	0.24	0.35	0.21	0.21	0.20	0.23	—
	3.10	1.69	3.15	3.87	3.10	2.68	—
	4.21	3.20	5.25	5.23	4.85	2.18	—
	0.00	0.00	-0.30	0.00	0.00	0.00	—
	4.21	3.20	4.95	5.23	4.85	2.18	—
	0.25	0.21	0.50	0.70	0.70	0.67	—
	3.96	2.99	4.45	4.53	4.15	1.50	—
	0.16	0.13	0.18	0.19	0.18	0.06	—
Key metrics
	4.96	4.18	5.85	5.99	5.64	2.94	—
	14.30%	11.40%	20.80%	20.40%	22.00%	12.60%	—
	11.40%	8.10%	15.80%	15.40%	16.20%	6.40%	—
	—	1.70%	—	2.70%	—	1.40%	—
	35.30%	57.70%	—	—	—	—	—
	-4.60%	99.30%	—	—	—	—	—

Metric	TTM	FY26	FY25	FY24
Income statement
	128.90	119.86	94.58	—
	7.88	8.14	9.22	—
	118.87	109.76	86.74	—
	104.57	96.83	67.18	—
	0.00	0.00	0.00	—
	6.46	6.67	6.42	—
	2.38	2.47	1.58	—
	1.01	0.97	0.77	—
	11.81	12.12	11.48	—
	17.89	18.24	17.06	—
	-0.30	0.00	0.00	—
	17.59	18.24	17.06	—
	1.66	2.11	3.02	—
	15.93	16.13	14.04	—
	0.66	0.67	0.62	—
Key metrics
	20.98	21.68	19.41	—
	16.28%	18.10%	20.50%	—
	12.36%	13.50%	14.80%	—
	—	9.30%	9.80%	—
	—	26.70%	—	—
	—	14.90%	—	—
	—	-45.69	-15.52	—
	—	-2.49	-0.68	—
	—	0.10	0.01	—
	—	22.77	0.69	—
	—	180.7	99.0	—
Balance sheet
	—	273.82	218.38	—
	—	238.09	187.02	—
	—	0.05	0.55	—
	—	33.37	11.89	—
	—	41.63	24.59	—
	—	4.95	4.39	—
	—	21.64	19.65	—
	—	15.68	10.84	—
	—	52.08	29.11	—
	—	22.82	1.24	—
	—	22.82	1.24	—
	—	0.00	0.00	—
	—	218.12	184.80	—
Cash flow
	—	-40.18	-9.56	—
	—	1.62	2.63	—
	—	35.40	1.53	—
	—	5.51	5.96	—

Compounded growth

Standalone

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Sales CAGR 10Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Profit CAGR 10Y: —
Sales YoY (TTM): —
Profit YoY (TTM): —

Consolidated

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Sales CAGR 10Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Profit CAGR 10Y: —
Sales YoY (TTM): —
Profit YoY (TTM): —

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Jun 2026

Promoter holding: 23.63%

Holder	Type	Holding	Previous	Change
PREMIER FISCAL SERVICES PRIVATE LIMITED	Promoter	21.83%	—	—
JMS MINES & MINERALS PRIVATE LIMITED	Public	3.25%	—	—
ANUPRIYA CONSULTANTS PVT LTD	Public	1.84%	—	—
DORITE TRACON PRIVATE LIMITED	Public	1.56%	—	—
SANJAY KUMAR	Public	1.53%	—	—
VAB VENTURES LIMITED	Promoter Group	1.42%	—	—
RAJABABU SAMPATRAO BANDELA	Public	1.41%	—	—
SUBHASH CHAND BHURA TRUSTEEOF ANUJ BHURA WELFARE TRUST	Promoter Group	0.32%	—	—
MIRAJ DIGVIJAY SHAH	Public	0.16%	—	—
ENFORCEMENT DIRECTORATE RAIPUR	Public	0.03%	—	—
VINOD BAID	Promoter Group	0.02%	—	—
PRUDENTIAL INVESTMENT LIMITED	Promoter Group	0.02%	—	—
INDIA SECURITIES BROOKING PRIVATE LIMITED	Promoter Group	0.02%	—	—
ARIHANT BAID	Promoter	0.00%	—	—
GOPALAKRISHNAN MURALIDHARAN TIRUVARUR	Promoter Group	0.00%	—	—

Public shareholders are disclosed individually only above 1%.

Filings & corporate actions

Recent announcements

Pursuant to Regulation 47 of SEBI (LODR) Regulations, 2015, please find enclosed herewith Newspaper publication of AGM Notice and eVoting related instructions advertisement published in ....9 Sep 2026 · Company Update / Newspaper Publication
We are pleased to inform that our subsidiary company, M/s Deccan Remedies Limited has received approval from the Drugs Control Administration, Government of Andhra Pradesh granting License ....8 Sep 2026 · Company Update / General
With reference to the subject matter, As per the Regulation 34 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we hereby submits 41st Annual Report of Gennex ....8 Sep 2026 · Others / Reg. 34 (1) Annual Report
Pursuant to Regulation 42 of SEBI (LODR) Regulations, 2015, the Register of Members and Share Transfer Books of the Company will remain closed from September 23, 2026 to September 30, 2026 ....4 Sep 2026 · Corp. Action / Book Closure
1. Draft Directors''/ Board Report for the Financial Year March 31, 2026; 2. The 41st Annual General Meeting of the Company to be held on Wednesday, September 30, 2026 at 12:30 P.M. through ....4 Sep 2026 · Board Meeting / Outcome of Board Meeting
Gennex Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/09/2026 ,inter alia, to consider and approve 1. To decide regarding ....27 Aug 2026 · Board Meeting / Board Meeting
Pursuant to Regulation 47 of SEBI (LODR) Regulations, 2015, please find enclosed herewith Newspaper publication on Unaudited (Standalone and Consolidated) Financial Results for the Quarter ....17 Aug 2026 · Company Update / Newspaper Publication
In just concluded Meeting of Board of Directors, the Board approved and considered the following items: 1. Unaudited Standalone and Consolidated Financial Statement for the Quarter ended ....14 Aug 2026 · Result / Financial Results
In just concluded Meeting of Board of Directors, the Board Approved and considered the following items: 1. Unaudited (Standalone and Consolidated) Financial Statements for the Quarter ....14 Aug 2026 · Board Meeting / Outcome of Board Meeting
Pursuant to Regulation 47 of SEBI (LODR), Regulations, 2015, please find enclosed herewith Newspaper Publication regarding Meeting of the Board of Directors of the Company scheduled to ....30 Jul 2026 · Company Update / Newspaper Publication
Gennex Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve 1. The Unaudited Financial ....29 Jul 2026 · Board Meeting / Board Meeting
With reference to the captioned subject matter, pursuant to Regulation 74(5) of SEBI (DP) Regulations, 2018, we hereby submit the certificate received from the M/s R&D Infotech Private ....17 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Notice is hereby given that in pursuance of SEBI (PIT) Regulations, 2015 and Company''s Code of Conduct for Regulating, Monitoring and Reporting of Trading by Insiders, the Trading Window ....23 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
The Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011 on June ....10 Jun 2026 · Insider Trading / SAST / Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011 on June ....10 Jun 2026 · Insider Trading / SAST / Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on June 10, 2026 for Premier Fiscal Services Pvt Ltd10 Jun 2026 · Insider Trading / SAST / Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on June 10, 2026 for Premier Fiscal Services Pvt Ltd10 Jun 2026 · Insider Trading / SAST / Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
Pursuant to Regulation 47 of SEBI (LODR) Regulations, 2015, please find enclosed herewith Newspaper publication on Audited (Standalone and Consolidated) Financial Results for the Quarter ....1 Jun 2026 · Company Update / Newspaper Publication
In just concluded Meeting of Board of Directors, the Board approved and considered the following items: 1. Audited Standalone & Consolidated Financial Results for the Quarter and Year ....30 May 2026 · Result / Financial Results
In just concluded Meeting of Board of Directors, the Board Approved and considered the following items: 1. Audited Standalone & Consolidated Financial results for the Quarter & Year Ended ....30 May 2026 · Board Meeting / Outcome of Board Meeting
In compliance with Regulation 24A of SEBI (LODR) Regulations, 2015, Board appointed M/s. Mohammed Tausif Shamim & Co., practicing Company Secretary, Kolkata as Secretarial Auditor of the ....30 May 2026 · Company Update / Reg.24(A)-Annual Secretarial Compliance
We refer to your email of 25th May, 2026 seeking clarification on your observation regarding significant movement noticed by the Exchange in the price of our company security at your exchange ....26 May 2026 · Company Update / General
The Exchange has sought clarification from Gennex Laboratories Ltd on May 25, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant ....25 May 2026 · Company Update / Clarification
Pursuant to Regulation 47 of SEBI (LODR) Regulations, 2015, please fine enclosed herewith Newspaper Publication regarding Meeting of the Board of Directors of the Company Scheduled to be ....20 May 2026 · Company Update / Newspaper Publication
Gennex Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 ,inter alia, to consider and approve With reference to the above ....19 May 2026 · Board Meeting / Board Meeting
In compliance to Regulation 44 of SEBI (LODR) Regulations, 2015, as amended from time to time (Listing Regulations), please find enclosed herewith voting results of electronic Extraordinary ....13 May 2026 · AGM/EGM / EGM
Pursuant to Reg.30 of SEBI (LODR) Regulations, 2015, we are pleased to provide hereunder the proceedings of Extraordinary General Meeting (EGM) of the Company held on Tuesday, May 12, 2026 ....12 May 2026 · AGM/EGM / EGM
Pursuant to Regulation 47 of SEBI of SEBI (LODR) Regulations, 2015, please find enclosed herewith Newspaper Publication of EGM Notice and eVoting related instructions advertisement published ....21 Apr 2026 · Company Update / Newspaper Publication
Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015 read with Schedule III and in furtherance to our intimation date April 16, 2026 and revised intimation dated April 17, 2026, we ....20 Apr 2026 · AGM/EGM / EGM
Revised outcome With reference to our earlier letter dated April 16, 2026, in this connection we would like to submit the revised outcome of the Board Meeting as follows: 1. Convening ....17 Apr 2026 · Company Update / Revision of outcome
In just concluded Meeting of Board of Directors, the Board Approved and considered the following items: 1. Convening of an Extraordinary General Meeting ('EGM') of the Company on Tuesday, ....16 Apr 2026 · Board Meeting / Outcome of Board Meeting
With reference to the captioned subject matter, pursuant to Regulation 74(5) of SEBI (DP) Regulations, 2018, we hereby submit the certificate received from the M/s. R&D Infotech Private ....13 Apr 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Gennex Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 16/04/2026 ,inter alia, to consider and approve 1. To decide regarding ....8 Apr 2026 · Board Meeting / Board Meeting
Notice is hereby given that in pursuance of SEBI (PIT) Regulations, 2015 and Company''s Code of Conduct for Regulating, Monitoring and Reporting of Trading by Insiders, the Trading Window ....25 Mar 2026 · Insider Trading / SAST / Closure of Trading Window
Pursuant to Regulation 47 of SEBI (LODR) Regulations, 2015, please find enclosed herewith Newspaper Publication on Unaudited (Standalone & Consolidated) Financial Results for the Quarter ....17 Feb 2026 · Company Update / Newspaper Publication
Pursuant to Regulation 30 of SEBI(LODR) Regulations, 2015, we wish to inform you that the Board of Directors of the Company in their meeting held today i.e. February 14, 2026 reconstituted ....14 Feb 2026 · Company Update / General
Pursuant to Regulation 30 read with Part A of Schedule III of SEBI (LODR) Regulations, 2015, we would like to inform you that based on recommendation of Nomination and Remuneration Committee ....14 Feb 2026 · Company Update / Change in Management
With reference to above captioned subject matter, this is to inform you that Ms. Shilpa Bung, Non-Executive Independent Women Director has tendered her resignation from the Board as Director ....14 Feb 2026 · Company Update / Resignation of Director
Unaudited (Standalone and Consolidated) Financial Results for 31.12.2025 along with Limited Review Report thereon.14 Feb 2026 · Result / Financial Results
1. Unaudited (Standalone and Consolidated) Financial Statements for the Quarter and Nine months ended December 31, 2025 2. Limited Review Report from the Statutory Auditor on Unaudited ....14 Feb 2026 · Board Meeting / Outcome of Board Meeting

Board meetings

14 Aug 2026 Board Meeting - Financial Results